Mereo BioPharma Group plc (MREO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - Mereo is a rare disease company focused on developing treatments for conditions such as osteogenesis imperfecta (OI) [1][2] - The company has three clinical programs, with two of them being in late-stage development [2] Patient Impact - The presentation highlighted the personal stories of patients like Martin, who has Type 3 OI and has been on bisphosphonate treatment since he was six months old, experiencing hundreds of fractures [2] - The impact of OI on patients' lives is significant, but individuals like Martin are managing to pursue their education and careers despite the challenges [2]